Loading…
GSK plc is projected to rise to $63.29 by 2027, a +22% move from its current price of $51.98. GSK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 29 | $51.25 | $52.01 | $52.78 | +0.05% |
| Jul 30 | $50.96 | $52.03 | $53.13 | +0.10% |
| Jul 31 | $50.75 | $52.06 | $53.41 | +0.15% |
| Aug 1 | $50.57 | $52.09 | $53.64 | +0.21% |
| Aug 2 | $50.43 | $52.11 | $53.86 | +0.26% |
| Aug 3 | $50.29 | $52.14 | $54.06 | +0.31% |
| Aug 4 | $50.17 | $52.17 | $54.24 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $50.17 | $52.17 | $54.24 | +0.36% |
| Week 2 | $49.55 | $52.35 | $55.32 | +0.72% |
| Week 3 | $49.11 | $52.54 | $56.21 | +1.08% |
| Week 4 | $48.78 | $52.73 | $57.01 | +1.45% |
| Week 5 | $48.50 | $52.92 | $57.74 | +1.81% |
| Week 6 | $48.28 | $53.11 | $58.43 | +2.18% |
| Week 7 | $48.08 | $53.30 | $59.09 | +2.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GSK plc is a healthcare company that researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments and offers vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. The company also provides general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions, and focuses on discovery and development of oral small molecule therapies for oncology and inflammatory diseases.
It has a collaboration with CureVac to develop mRNA vaccines for infectious diseases and a strategic research collaboration with Engitix Ltd. to identify novel targets driving liver fibrosis regression, along with an alliance with AN2 Therapeutics for TB. GSK was formerly GlaxoSmithKline plc and changed its name to GSK plc in May 2022.
The company was founded in 1715 and is headquartered in London, United Kingdom.
GSK plc trades as a healthcare stock with a current price of $50.74 and a market capitalization of $101.62B, ranking 148. The shares sit near pivotal levels, with a 30-day range spanning from $46.16 to $55.78 and a sentiment that is Neutral. Technical indicators show a near-term balance around the $50s, with a 50-day simple moving average of $51.48 and a 200-day simple moving average of $51.34, while support sits at $50.04 and resistance at $53.66.
A major floor 7.1% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 3.2% above — a clean break opens room to run.
A major ceiling 13.9% above — clearing it would confirm fresh momentum.
Key GSK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GSK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $50.86 | Buy | $51.29 | Buy |
| MA 10 | $51.38 | Buy | $51.44 | Buy |
| MA 20 | $52.03 | Sell | $51.66 | Buy |
| MA 50 | $51.50 | Buy | $51.97 | Buy |
| MA 100 | $53.00 | Sell | $52.07 | Sell |
| MA 200 | $51.38 | Buy | $50.39 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.36 | Neutral |
| Stoch RSI (14) | 67.02 | Neutral |
| CCI (20) | -4.40 | Neutral |
| Williams %R (14) | -40.85 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -1.03 | Sell |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 59.15 | Neutral |
| TRIX (15) | -0.01 | Sell |
| Awesome (5,34) | -1.03 | Sell |
| Ultimate (7,14,28) | 50.39 | Neutral |
| Momentum (10) | -0.80 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 50.79 | Buy |
| ADX (14) | 9.44 | Neutral |
| ATR (14) | 0.72 | Info |
The near-term technical picture is Neutral, with RSI at 40 indicating modest momentum. The price sits around the key moving averages, with the SMA50 at $51.48 and the SMA200 at $51.34, suggesting a close relation to short- to medium-term trend lines. Traders should note the immediate support at $50.04 and resistance at $53.66, with the 30-day price range running from $46.16 to $55.78.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $47.65 | $51.98 | $67.56 | 0% | Neutral | |
| $51.88 | $63.29 | $80.68 | +22% | Bullish | |
| $61.75 | $76.75 | $100.52 | +48% | Bullish | |
| $70.98 | $89.60 | $119.87 | +72% | Bullish | |
| $70.55 | $90.26 | $122.94 | +74% | Bullish | |
| $75.10 | $97.26 | $134.59 | +87% | Bullish | |
| $83.15 | $108.91 | $152.86 | +110% | Bullish | |
| $86.39 | $114.35 | $162.58 | +120% | Bullish | |
| $102.85 | $137.50 | $197.84 | +165% | Bullish | |
| $114.44 | $154.44 | $224.70 | +197% | Bullish | |
| $154.64 | $217.69 | $331.93 | +319% | Bullish | |
| $273.51 | $412.94 | $675.02 | +694% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $47.65 | $51.98 | $61.09 | +0.00% |
| August 2026 | $46.52 | $54.28 | $64.57 | +4.42% |
| September 2026 | $46.42 | $54.47 | $65.38 | +0.35% |
| October 2026 | $45.66 | $53.81 | $65.06 | -1.21% |
| November 2026 | $46.17 | $54.61 | $66.43 | +1.49% |
| December 2026 | $46.54 | $55.25 | $67.56 | +1.16% |
Click any year to see its month-by-month GSK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect GSK to range from $47.65 to $67.56 through 2026. The $51.98 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The GSK price prediction for 2027 points to an average of $63.29 (low $51.88, high $80.68) — a potential gain of +22% on today's $51.98. Buyers look set to stay in control over this stretch.
In 2028, GSK is projected to trade between $61.75 and $100.52, averaging $76.75 — a potential gain of +48% from today's $51.98. That is up +21% on the projected 2027 average. Momentum favours further upside here.
GSK plc's 2029 outlook centres on $89.60, within a $70.98 to $119.87 range. That is up +17% on the projected 2028 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, GSK could reach as high as $122.94, with a base case around $90.26 and support toward $70.55 — roughly +74% from $51.98. Momentum favours further upside here.
Expect GSK to range from $75.10 to $134.59 through 2031. The $97.26 average target implies a +87% move from current prices. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The GSK price prediction for 2032 points to an average of $108.91 (low $83.15, high $152.86) — a potential gain of +110% on today's $51.98. Momentum favours further upside here.
In 2033, GSK is projected to trade between $86.39 and $162.58, averaging $114.35 — a potential gain of +120% from today's $51.98. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
GSK plc's 2034 outlook centres on $137.50, within a $102.85 to $197.84 range. That is up +20% on the projected 2033 average. That marks a +165% change versus current levels. Momentum favours further upside here.
By 2035, GSK could reach as high as $224.70, with a base case around $154.44 and support toward $114.44 — roughly +197% from $51.98. Buyers look set to stay in control over this stretch.
Expect GSK to range from $154.64 to $331.93 through 2040. The $217.69 average target implies a +319% move from current prices. That is up +41% on the projected 2035 average. Momentum favours further upside here.
The GSK price prediction for 2050 points to an average of $412.94 (low $273.51, high $675.02) — a potential gain of +694% on today's $51.98. Buyers look set to stay in control over this stretch.
Investing $1,000 in GSK today (≈ 19.238169 GSK) could be worth
$7,944.25
+$6,944.25 (+694%) by 2050 · US Dollar
Based on the average projected GSK price of $412.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GSKwould be worth at today's price.
$1,000 invested in GSK on Jul 28, 2025 (≈ 26.702269 GSK) would be worth
$1,387.98
+$387.98 (+38.8%) today · 1.39× · US Dollar
Based on a GSK entry price of $37.45 vs. today's $51.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $50.04 | $1,038.77 | +3.9% |
| 1 month ago | $52.5 | $990.1 | -1.0% |
| 3 months ago | $54.47 | $954.29 | -4.6% |
| 6 months ago | $50.1 | $1,037.52 | +3.8% |
| 1 year ago | $37.45 | $1,387.98 | +38.8% |
| All time (5.0y) ago | $40.1 | $1,296.26 | +29.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GSK forecast.
Our base-case forecast reaches $100.00 around 2032.
Implied market cap at $100.00: $200.28B
The year-by-year forecast shows a bullish trajectory after 2026, with the 2026 average price at $50.74 and a 2027 average of $61.48 (ROI 21.2%, sentiment BULLISH). The path continues higher through 2028 ($74.61), 2029 ($86.44), and 2030 ($86.86) with strong returns (71.2% by 2030). By 2031 the average reaches $93.84 (ROI 85%), and by 2032 it is $104.52 on average (ROI 106%) with a max of $146.71.
The forecast extends through 2033 ($109.27 avg, ROI 115.3%), 2034 ($131.67 avg, ROI 159.5%), and 2035 ($147.50 avg, ROI 190.7%). It remains bullish into 2040 (avg $207.50, ROI 308.9%) and culminates in 2050 with an average of $389.04, a max of $635.98, and a projected ROI of 666.7%. These figures reflect a rising path with bullish sentiment across the long term, but they are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast shows an average price of $86.86, a low of $67.88, and a max of $118.34 in 2030, with an ROI of 71.2% and a BULLISH sentiment.
The long-term forecast indicates a bullish trajectory from 2027 onward, with the average price rising to $389.04 by 2050 and an ROI of 666.7%. However these are estimates and not guarantees.
Yes. The 2032 forecast shows a max of $146.71 and an average of $104.52, indicating a path to exceed $100 by 2032.
Current price is $50.74 and market cap is $101.62B, with a rank of 148.
The 30-day range is $46.16 to $55.78, RSI is 40, SMA50 is $51.48, SMA200 is $51.34, with a support at $50.04 and resistance at $53.66, and annualized volatility of 30%.
GSK plc Community Discussion
0Share your GSK plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.